In particular, miR-125b overexpression sensitizes HCC cells to doxorubicin and sorafenib treatments, and negatively regulates MDR genes, including ABCC1, ABCG2, and ABCB1, contributing to drug efflux from cancer cells. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.